---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-11-07T02:06:40.531469'
end_time: '2026-11-07T02:22:34.921792'
duration_seconds: 954.39
template_file: templates/disease_pathophysiology_research.md
template_sha: "f452f0a9c7e3536175154b9683c45663f686f283"
template_variables:
  disease_name: Periventricular Nodular Heterotopia 7
  mondo_id: MONDO:0014966
  category: Mendelian
  causal_genes: NEDD4L
  omim_id: OMIM:617201
  synonyms: periventricular nodular heterotopia 7; PVNH7; periventricular nodular
    heterotopia type 7; NEDD4L periventricular nodular heterotopia; PVNH7; periventricular
    nodular heterotopia caused by mutation in NEDD4L
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
fell_back: true
requested_provider: falcon
provider_attempts:
- provider: falcon
  succeeded: false
  error_type: ProviderNotConfiguredError
  remedy: the provider is not configured
  retryable: false
- provider: openscientist
  succeeded: true
citation_count: 20
reference_validation:
  total_references: 20
  verified: 20
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  quotes_checked: 18
  quotes_valid: 16
  quotes_unsupported: 2
  unsupported_quote_references:
  - PMID:31922594
  - PMID:28212375
  relevance_assessed: 20
  on_topic: 8
  off_topic: 2
  off_topic_references:
  - PMID:18498246
  - PMID:20675381
  needs_review: true
  validator_version: 0.5.1
term_validation:
  total_terms: 28
  verified: 27
  not_found: 0
  obsolete: 0
  unverifiable: 1
  confabulation_rate: 0.0
  labels_checked: 9
  labels_matching: 4
  labels_mismatched: 5
  mislabelled_terms:
  - term_id: MONDO:0014966
    reported_labels:
    - MONDO
    ontology_label: periventricular nodular heterotopia 7
  - term_id: HP:0001252
    reported_labels:
    - Clinical sign
    ontology_label: Hypotonia
  - term_id: HP:0000308
    reported_labels:
    - Physical malformation
    ontology_label: Microretrognathia
  - term_id: HP:0000486
    reported_labels:
    - Clinical sign
    ontology_label: Strabismus
  - term_id: HP:0000047
    reported_labels:
    - Physical malformation
    ontology_label: Hypospadias
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Periventricular_Nodular_Heterotopia_7-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Periventricular_Nodular_Heterotopia_7-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Periventricular Nodular Heterotopia 7
- **MONDO ID:** MONDO:0014966 (if available)
- **Causal gene(s):** NEDD4L
- **OMIM:** OMIM:617201
- **Synonyms:** periventricular nodular heterotopia 7; PVNH7; periventricular nodular heterotopia type 7; NEDD4L periventricular nodular heterotopia; PVNH7; periventricular nodular heterotopia caused by mutation in NEDD4L
- **Category:** Mendelian

Many disease names are serial numbers ("... autosomal dominant 64", "... 26") that
do not say which gene the disease is about, and a similarly named disease with a
different gene is easy to research by mistake. Research the disease with the MONDO
ID and causal gene given above, and name its causal gene in your first paragraph.
If the name seems to point to a different gene or OMIM entry, follow the
identifiers above.

## Research Objectives

Please provide a comprehensive research report on **Periventricular Nodular Heterotopia 7** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Periventricular Nodular Heterotopia 7 (PVNH7, NEDD4L): Comprehensive Disease Report

**Disease:** Periventricular Nodular Heterotopia 7 (PVNH7)
**Causal gene:** **NEDD4L** (NEDD4-2; HECT-type E3 ubiquitin–protein ligase; chromosome 18q21; HGNC:7728; NCBI Gene 23327; UniProt Q96PU5)
**OMIM:** 617201 | **MONDO:** MONDO:0014966
**Category:** Mendelian, autosomal dominant malformation of cortical development

---

## Summary

Periventricular Nodular Heterotopia 7 (PVNH7) is an ultra-rare, autosomal-dominant malformation of cortical development caused by **mostly de novo heterozygous missense variants in NEDD4L**, the gene encoding the HECT-type E3 ubiquitin–protein ligase **NEDD4-2** on chromosome 18q21. The disease was defined by Broix et al. in 2016, who showed that missense mutations clustering in the catalytic **HECT domain** of NEDD4L cause periventricular nodular heterotopia (PNH) accompanied by a distinctive syndromic constellation. The causal gene is NEDD4L — this is important to state up front because "periventricular nodular heterotopia" is a genetically heterogeneous radiological entity, and the far more common classic form is X-linked and caused by *FLNA*, a different gene with a different clinical and inheritance profile.

Mechanistically, PVNH7 arises when mutant NEDD4-2 protein — which is sensitive to proteasomal degradation — deregulates **AKT–mTORC1 signaling** and the **Dab1/Reelin** pathway, impairing neurogenesis, neuronal positioning, and the terminal translocation of migrating neurons. Neurons that fail to migrate are retained as **bilateral periventricular nodules** lining the lateral ventricles. The condition is not a simple loss-of-function/haploinsufficiency disorder: both mutant protein and excess wild-type NEDD4L perturb cortical development, pointing to dosage/activity sensitivity. Clinically, PVNH7 presents as a recognizable syndrome of bilateral PNH, perisylvian polymicrogyria, cleft palate, 2–3 toe syndactyly, seizures (including infantile spasms), hypotonia, and variable global developmental delay/intellectual disability.

As of 2023, only **eight pathogenic NEDD4L variants across ~15 cases worldwide** had been reported, so population-level epidemiology, penetrance estimates, and natural-history data remain largely undefined. Inheritance is autosomal dominant with documented parental mosaicism and marked intra-familial variability. There is **no disease-specific or curative therapy**; management is symptomatic and multidisciplinary (antiseizure medication, cleft-palate repair, developmental/rehabilitative therapy, and genetic counseling). Because the disorder deregulates mTORC1/AKT, **mTOR inhibition (rapamycin/sirolimus) is a mechanistic/theoretical target**, supported by rescue experiments in other mTORopathy models, but no clinical trials exist for PVNH7.

---

## 1. Disease Information

**Overview.** PVNH7 is a Mendelian malformation of cortical development (MCD) in the periventricular nodular heterotopia family. On brain MRI it is defined by nodules of gray-matter-isointense neurons that are ectopically retained along the walls of the lateral ventricles. PVNH7 specifically denotes the form caused by NEDD4L and is distinguished by a syndromic pattern that includes cortical malformation beyond the nodules themselves (typically perisylvian polymicrogyria), orofacial clefting, and distal limb anomalies.

**Key identifiers.**

| Resource | Identifier |
|---|---|
| OMIM | 617201 |
| MONDO | MONDO:0014966 |
| Gene (HGNC) | NEDD4L / HGNC:7728 |
| NCBI Gene / UniProt | 23327 / Q96PU5 |
| Chromosomal locus | 18q21 |
| Inheritance | Autosomal dominant (mostly de novo) |

ICD-10/ICD-11, Orphanet, and MeSH do not maintain a dedicated code that cleanly separates PVNH7 from the broader "periventricular nodular heterotopia" grouping; PNH overall maps to the malformations-of-cortical-development/neuronal-migration-disorder categories (ICD-10 Q04.8 "other congenital malformations of brain" is used pragmatically).

**Synonyms:** periventricular nodular heterotopia 7; PVNH7; periventricular nodular heterotopia type 7; NEDD4L periventricular nodular heterotopia; periventricular nodular heterotopia caused by mutation in NEDD4L.

**Source of information.** The knowledge base here is derived from **aggregated disease-level resources** (OMIM, MONDO) plus **individual patient case reports and small case series** in the primary literature — not from a large EHR cohort, because the disease is ultra-rare.

---

## 2. Etiology

**Primary cause — genetic.** PVNH7 is caused by heterozygous pathogenic missense variants in **NEDD4L**. The overwhelming majority are **de novo**, though inherited/familial transmission and parental somatic/germline mosaicism are documented. There is no known infectious or primary environmental cause.

**Genetic risk factors.** The causal variants themselves are the risk factor; they cluster in the catalytic HECT domain (with at least one recurrent WW-domain variant, p.Arg208Gln). No susceptibility loci or modifier genes have been formally established for PVNH7, given the tiny case count.

**Environmental risk factors / protective factors.** None established. No toxin, lifestyle, occupational exposure, dietary, or protective allele has been linked to PVNH7. Because the disorder is caused by highly penetrant de novo dominant variants, environmental contribution is expected to be minimal.

**Gene–environment interactions.** None described. This is a monogenic developmental malformation; GxE data are not available.

---

## 3. Phenotypes

Across the reported cases, PVNH7 produces a recurrent multi-system constellation. The table below summarizes the core phenotypes with suggested HPO terms and qualitative frequency.

| Phenotype | Type | HPO suggestion | Onset | Frequency (qualitative) |
|---|---|---|---|---|
| Bilateral periventricular nodular heterotopia | Imaging/structural sign | HP:0032388 (periventricular nodular heterotopia) | Congenital | ~All cases |
| Perisylvian polymicrogyria | Imaging/structural sign | HP:0002126 (polymicrogyria) | Congenital | Frequent |
| Seizures / infantile spasms | Clinical sign | HP:0001250 (seizure); HP:0012469 (infantile spasms) | Infancy–childhood | Most cases |
| Global developmental delay / intellectual disability | Clinical sign | HP:0001263; HP:0001249 | Infancy onward | Frequent, variable |
| Cleft palate | Physical malformation | HP:0000175 (cleft palate) | Congenital | Frequent |
| 2–3 toe syndactyly | Physical malformation | HP:0001770 (toe syndactyly) | Congenital | Frequent |
| Hypotonia | Clinical sign | HP:0001252 | Infancy | Common |
| Absent/delayed speech & walking | Developmental | HP:0001344; HP:0002540 | Childhood | Common |
| Microretrognathia | Physical malformation | HP:0000308 | Congenital | Reported |
| Strabismus | Clinical sign | HP:0000486 | Childhood | Reported |
| Hypospadias | Physical malformation | HP:0000047 | Congenital | Reported (males) |

"All patients reported with NEDD4L HECT domain mutations showed periventricular nodular heterotopia, and most had seizures, cortex anomalies, cleft palate and syndactyly" (PMID: 28515470).

**Severity and progression.** The structural brain malformation is static (non-progressive), but its clinical consequences — epilepsy and developmental impairment — evolve over time. Severity is **highly variable**, even within a single family: a familial case carrying p.Arg208Gln spanned the range from **isolated bilateral PNH** to **severe neurodevelopmental delay with refractory seizures** — "Phenotypic features in the proband consisted of severe neurodevelopmental delay, refractory seizures, bilateral PNH, and perisylvian polymicrogyria" (PMID: 32117442). A mosaic-carrier father had an affected prior fetus with hypokinesia and flexion contractures, suggesting the prenatal spectrum extends to a severe fetal akinesia-like presentation (PMID: 30393983).

**Quality-of-life impact.** No formal EQ-5D/SF-36/PROMIS data exist for PVNH7. Qualitatively, QoL is driven by seizure burden (which may be drug-resistant) and by intellectual disability/motor impairment that affect speech, ambulation, and independence. Cleft palate adds feeding/speech burden early in life.

---

## 4. Genetic / Molecular Information

**Causal gene.** NEDD4L (neural precursor cell expressed, developmentally down-regulated 4-like), encoding **NEDD4-2**, a HECT-type E3 ubiquitin–protein ligase (HGNC:7728; NCBI Gene 23327; UniProt Q96PU5; chromosome 18q21). "Missense mutations in NEDD4L mapping to the HECT domain of the encoded E3 ubiquitin ligase lead to PNH associated with toe syndactyly, cleft palate and neurodevelopmental delay" (PMID: 27694961).

**Protein architecture.** NEDD4-2 contains an N-terminal **C2 domain** (membrane/calcium binding), **four WW domains** that bind PY/L-PxY motifs in substrates, and a C-terminal catalytic **HECT domain** that transfers ubiquitin (PMID: 12698368; PMID: 18498246).

**Pathogenic variants.** PVNH7 variants are predominantly **missense** and cluster in the **HECT domain**, with a recurrent WW-domain variant also reported:

| Variant (protein) | cDNA / notes | Domain | Classification |
|---|---|---|---|
| p.Glu893Lys (= p.Glu873Lys) | NM_001144967.2 c.2677G>A (= NM_015277 c.2617G>A) — recurrent | HECT | Pathogenic |
| p.Leu706Pro | c.2117T>C — de novo | HECT | Likely pathogenic (ACMG) |
| p.Tyr679His | — | HECT | Pathogenic |
| p.Gln900Arg | — | HECT | Pathogenic |
| p.Arg208Gln | familial, variable expressivity | WW domain | Pathogenic |

A de novo heterozygous missense mechanism is documented: "de novo heterozygous missense mutation in the NEDD4L gene (NM_015277: c.2617G>A; p.Glu873Lys)" (PMID: 28515470). Note the nomenclature caveat: the variant initially described as "novel" p.Glu873Lys (NM_015277) is **identical** to p.Glu893Lys (NM_001144967) reported by Broix et al.; a published Author Correction clarified it is **recurrent, not novel** (PMID: 31028281). The p.Leu706Pro variant was reported as "a heterozygous c.2117T>C (p.Leu706Pro) variant… a de novo variant… predicted to be likely pathogenic according to the American College of Medical Genetics Guidelines" (PMID: 31922594).

**Allele frequency.** These are private/de novo disease alleles essentially absent from population databases (gnomAD); no appreciable population allele frequency.

**Somatic vs germline.** Germline (constitutional) in affected individuals; **parental mosaicism** (somatic/germline) has been documented — "Molecular testing from peripheral blood identified the healthy father to carry the NEDD4L variant in mosaic state" (PMID: 30393983).

**Functional consequences.** PVNH7 is **not a simple loss-of-function disorder.** PNH-associated mutants are **sensitive to proteasomal degradation** — "Cellular and expression data showed sensitivity of PNH-associated mutants to proteasome degradation" (PMID: 27694961) — and both mutant protein and **excess wild-type NEDD4L** disrupt neurodevelopment, indicating dosage/activity sensitivity rather than haploinsufficiency. A functional case study of p.Gln900Arg found the variant "did not affect mRNA expression, whereas WB and IF results indicated that the level of muta[nt protein]…" was altered, consistent with protein-level destabilization (PMID: 36934385). The net downstream effect is **deregulation of mTORC1 and AKT activities**.

**Modifier genes / epigenetics / chromosomal abnormalities.** No specific modifier genes or epigenetic marks are established for PVNH7. In the broader PNH population, array-CGH detects causative copy-number variants in a substantial subset (~35.7% of PNH vs 9.1% of polymicrogyria), underscoring extreme genetic heterogeneity of the PNH phenotype generally (PMID: 30683929) — but PVNH7 proper is defined by the point mutations in NEDD4L, not CNVs.

---

## 5. Environmental Information

No environmental factors, lifestyle factors, toxins, radiation exposures, or infectious agents have been implicated in PVNH7. It is a monogenic developmental disorder. This section is **not applicable** beyond noting the absence of evidence.

---

## 6. Mechanism / Pathophysiology

### Ordered causal chain (initiating lesion → clinical manifestation)

1. A **de novo (or mosaic-inherited) heterozygous missense mutation in NEDD4L**, clustering in the catalytic HECT domain (or a WW domain), arises in the germline → produces a **structurally altered, proteasome-sensitive NEDD4-2 protein** (demonstrated: proteasome sensitivity; PMID: 27694961).
2. The altered NEDD4-2 **deregulates its E3 ubiquitin-ligase activity and substrate handling** → **abnormal signaling output**, specifically "deregulation of mTORC1 and AKT activities" (demonstrated in overexpression systems; PMID: 27694961).
3. In parallel, excess/dysregulated NEDD4L activity **disrupts Dab1**, a key node of the **Reelin pathway** that guides neuronal migration — "Excess wild-type NEDD4L leads to disruption of Dab1 and mTORC1 pathways" (PMID: 27694961).
4. Deregulated AKT–mTORC1 and Dab1/Reelin signaling **impairs neurogenesis, neuronal positioning, and terminal translocation** of migrating cortical neurons — "PNH-related mutants and excess wild-type NEDD4L affect neurogenesis, neuronal positioning and terminal translocation" (demonstrated by in utero electroporation; PMID: 27694961).
5. Neurons that fail to complete radial migration **are retained ectopically along the lateral ventricles → bilateral periventricular nodular heterotopia**; cortical organization is further disturbed → **perisylvian polymicrogyria** (inferred from imaging + migration defect).
6. The abnormal cortical circuitry, combined with NEDD4-2's physiological role in down-regulating the **AMPA receptor GluA1 subunit** (loss of this regulation elevates neuronal activity), **lowers seizure threshold → epilepsy/infantile spasms** — "Nedd4-2 mediates neuronal activity and seizure susceptibility through ubiquitination of GluA1 subunit of the… AMPA receptor" (demonstrated in Nedd4-2-deficient mice; PMID: 28212375; mechanistic bridge to PVNH7 inferred).
7. Disrupted cortical development and NEDD4-2's broader developmental roles **manifest systemically as developmental delay/intellectual disability, hypotonia, and non-CNS malformations (cleft palate, toe syndactyly)** (inferred from consistent clinical co-occurrence).

```
NEDD4L HECT/WW missense (de novo)
        │  (proteasome-sensitive mutant NEDD4-2)
        ▼
 Deregulated E3 ligase activity
        ├──────────────► ↑/dysreg AKT–mTORC1 ──┐
        └──────────────► disrupted Dab1/Reelin ─┤
                                                ▼
                       Impaired neurogenesis, positioning,
                             terminal translocation
                                                ▼
                 Bilateral periventricular nodules + polymicrogyria
                                                │
                        (abnormal circuits + loss of GluA1 control)
                                                ▼
                     Epilepsy / infantile spasms, DD/ID, hypotonia
                     + syndromic: cleft palate, 2–3 toe syndactyly
```

### Supporting detail

**Molecular pathways.** PI3K–AKT–**mTORC1** is the central deregulated axis (PMID: 27694961). NEDD4-family ligases act **downstream** of PI3K/PTEN–mTORC1 signaling and promote neurite/axonal growth; PTEN controls Nedd4-1 expression by modulating mTORC1 activity — "PTEN controls neurite growth by regulating Nedd4-1 expression" (PMID: 25157163). The **Reelin–Dab1** migration pathway is the second affected arm (PMID: 27694961).

**Cellular processes.** Neurogenesis, radial neuronal migration, neuronal positioning, and terminal translocation are the core affected processes. Suggested GO terms: **GO:0001764** (neuron migration), **GO:0022008** (neurogenesis), **GO:0021799** (cerebral cortex radially oriented cell migration), **GO:0016567** (protein ubiquitination), **GO:0032008** (positive regulation of TOR signaling).

**Protein dysfunction.** Mutant NEDD4-2 is destabilized/proteasome-sensitive with altered catalytic/substrate behavior — a complex, non-simple loss-of-function effect with evidence of dosage sensitivity (PMID: 27694961; PMID: 36934385). Nedd4-2 stability is itself regulated by an intramolecular WW–HECT PY-motif interaction and by SGK1/PKA phosphorylation with 14-3-3 binding (PMID: 18498246; PMID: 16716084).

**Cell types involved.** Cortical neural progenitors and migrating projection (pyramidal) neurons. Suggested CL terms: **CL:0000047** (neural stem cell / neural progenitor), **CL:0000679** (glutamatergic neuron), **CL:0000598** (pyramidal neuron).

**Ion channel / receptor links.** NEDD4-2's canonical substrate is the epithelial Na⁺ channel ENaC — "The epithelial Na(+) channel ENaC is the best studied example of a Nedd4/Nedd4-like substrate" (PMID: 12698368) — whose dysregulation causes the unrelated **Liddle syndrome** hypertension phenotype (PMID: 20675381). In brain, NEDD4-2 ubiquitinates the **AMPA receptor GluA1 subunit**; Nedd4-2-deficient mice show elevated neuronal activity and increased kainic-acid seizure susceptibility, normalized by genetically reducing GluA1 (PMID: 28212375).

**Context-dependence caveat.** Not all systems show the same magnitude of signaling change: Kato et al. (2017) found only **subtle AKT–mTOR deregulation in patient lymphoblastoid cell lines**, versus the robust effects in forced-overexpression/in-utero electroporation systems — a reminder that the quantitative mechanism is context-dependent.

---

## 7. Anatomical Structures Affected

**Organ / system level.** Primary organ: the **brain** (central nervous system). The disorder also affects **craniofacial** structures (palate → cleft palate; jaw → microretrognathia) and **distal limbs** (toes → 2–3 syndactyly), with occasional genitourinary involvement (hypospadias) and reported strabismus (ocular motility).

**Tissue and cell level.** Nervous tissue — specifically the developing cerebral cortex. Affected cell populations: neural progenitors and migrating cortical neurons (CL:0000047; CL:0000598).

**Subcellular level.** The pathology centers on the **ubiquitin–proteasome system** (cytoplasmic; mutant protein degraded by the proteasome) and on **mTORC1 signaling at the lysosomal surface/cytoplasm**. Suggested GO cellular component terms: **GO:0005737** (cytoplasm), **GO:0000502** (proteasome complex).

**Localization.** Nodules line the walls of the **lateral ventricles** (UBERON:0002285, lateral ventricle of the brain; periventricular region). Associated polymicrogyria is **perisylvian** (around the Sylvian fissure / insular cortex). Lateralization is characteristically **bilateral** in PVNH7 — a feature of diagnostic and prognostic importance. Suggested UBERON terms: **UBERON:0002285** (lateral ventricle), **UBERON:0000956** (cerebral cortex).

---

## 8. Temporal Development

**Onset.** The structural malformation is **congenital** (established during fetal corticogenesis). Clinical onset: seizures typically emerge in **infancy to childhood** (infantile spasms can be an early manifestation); developmental delay becomes apparent across infancy and early childhood. In the broader PNH-epilepsy population, "Mean seizure onset age was 7.9 years" (PMID: 37119372), though PVNH7's syndromic, bilateral pattern tends toward earlier and more severe presentations.

**Progression.** The brain malformation itself is **static/non-progressive**. The clinical course is dominated by epilepsy, which may be **self-limited, pharmacoresponsive, or drug-resistant** depending on malformation pattern, and by a **chronic, lifelong** developmental disability. Disease duration is lifelong.

**Patterns / critical periods.** The critical period is **fetal cortical neurogenesis and migration** (second trimester), when the malformation is laid down — the only true window for primary prevention would be preconception/prenatal. Post-natally there is no remission of the structural lesion; "remission" applies only to seizure control achieved with medication or, in selected drug-resistant focal cases, surgery.

---

## 9. Inheritance and Population

**Epidemiology.** PVNH7 is **ultra-rare**: "only eight NEDD4L pathogenic variants have been identified across 15 cases of PVNH7 worldwide" as of 2023 (PMID: 36934385). No reliable prevalence or incidence figures exist, and no separate Orphanet prevalence class is defined for PVNH7.

**Inheritance.** **Autosomal dominant.** The majority of cases are **de novo heterozygous missense** variants, but familial transmission occurs, and **parental somatic/germline mosaicism** is documented (PMID: 30393983).

**Penetrance and expressivity.** Penetrance appears high for carriers of a constitutional pathogenic variant, but **expressivity is strikingly variable** — the familial p.Arg208Gln pedigree ranged from isolated bilateral PNH to severe neurodevelopmental delay (PMID: 32117442). Formal penetrance estimates are not possible with so few cases.

**Anticipation / founder effects / consanguinity / carrier frequency.** No genetic anticipation (not a repeat-expansion disorder). No founder effect, ethnic clustering, or consanguinity role established. Carrier frequency is effectively nil in the general population (de novo dominant disease).

**Population demographics.** No sex predilection established. No geographic/ethnic clustering of the disease or of specific variants. The recurrent p.Glu893Lys/p.Glu873Lys variant is the most frequently reported allele but reflects a mutational hotspot rather than a population founder.

---

## 10. Diagnostics

**Imaging (first-line).** **Brain MRI** is the primary diagnostic modality: it demonstrates nodules of gray-matter-isointense neurons lining the lateral ventricles; in PVNH7 the nodules are **bilateral**, frequently with **perisylvian polymicrogyria**.

**Molecular confirmation.** Diagnosis is confirmed by **trio whole-exome sequencing** (proband + parents) with **Sanger confirmation** of a de novo NEDD4L variant — the standard approach "verified the genetic etiology using Trio-whole-exome and Sanger sequencing" (PMID: 36934385). WES is high-yield because it establishes de novo status and distinguishes PVNH7 from other genetic PNH forms. Gene panels for malformations of cortical development / neuronal migration disorders should include NEDD4L alongside FLNA, ARFGEF2, and others. **Chromosomal microarray (array-CGH)** is recommended as a first-line test in PNH generally (especially sporadic, non-classical cases) because CNVs are a cumulatively frequent cause (~35.7% in one PNH series; PMID: 30683929) — though PVNH7 itself is a point-mutation disorder.

**Differential diagnosis.** The principal genetic differentials are:

| Gene | Inheritance | Distinguishing features |
|---|---|---|
| **FLNA** (classic PNH) | X-linked dominant | Predominantly females; male prenatal lethality; cardiovascular, pulmonary (childhood interstitial lung disease), skeletal, GI involvement; no cleft palate + toe syndactyly constellation (PMID: 37422633; PMID: 30547349) |
| **ARFGEF2** | Autosomal recessive | Microcephaly, severe DD |
| **NEDD4L (PVNH7)** | Autosomal dominant (de novo) | Bilateral PNH + polymicrogyria + **cleft palate + 2–3 toe syndactyly** — a unique constellation |

"The unique constellation of clinical features in patients with NEDD4L mutations might help clinically distinguish them from patients with other genetic mutations including FLNA" (PMID: 28515470).

**Laboratory / biomarkers / electrophysiology.** No specific blood/urine biomarker exists. **EEG** is used to characterize seizures (and may show hypsarrhythmia in infantile spasms). No omics-based or liquid-biopsy diagnostic is established.

**Screening.** Because most cases are de novo, there is no population carrier-screening program. For families with an identified variant (including mosaic parents), **cascade testing and prenatal/preimplantation genetic testing** are feasible.

---

## 11. Outcome / Prognosis

**Survival/mortality.** PVNH7 is not primarily a lethal disorder postnatally; no specific survival or mortality statistics are published. The severe end of the prenatal spectrum (fetal hypokinesia/flexion contractures in an affected fetus; PMID: 30393983) indicates the possibility of a severe/lethal fetal presentation in some pregnancies.

**Morbidity and function.** The dominant morbidity is **epilepsy** (potentially drug-resistant) and **neurodevelopmental disability** (intellectual disability, motor delay, speech impairment). Epilepsy prognosis is stratified by nodule distribution:

| PNH pattern | Drug-resistance |
|---|---|
| Isolated single-nodule PNH | No drug-resistant seizures |
| **PVNH-Plus, bilateral nodules** (the PVNH7 pattern) | **Highest drug resistance (39%)** |

In a retrospective cohort of 100 PVNH patients with seizures, mean onset was 7.9 years; 10 had self-limited epilepsy, 35 more were pharmacoresponsive, 55 had ongoing seizures, and 23 met drug-resistance criteria; "PVNH-Plus with bilateral nodules demonstrated the highest proportion of drug resistance (39%)" (PMID: 37119372). Because PVNH7 characteristically presents as bilateral PNH plus an additional malformation (polymicrogyria), affected individuals fall into this **higher-severity stratum**.

**Complications and recovery.** Complications include refractory seizures, feeding/speech difficulty from cleft palate, and functional impairment. The structural brain lesion does not resolve; recovery is limited to seizure control and developmental gains with therapy.

**Prognostic factors.** Bilateral + syndromic malformation pattern (worse epilepsy prognosis), seizure burden, and degree of developmental delay are the main prognostic indicators. No molecular prognostic biomarker is validated; intra-familial variability (PMID: 32117442) limits genotype-based prediction.

---

## 12. Treatment

**No disease-modifying or NEDD4L-specific therapy exists.** Management is **symptomatic and multidisciplinary** (NCIT suggestions in parentheses):

- **Antiseizure medication** for epilepsy — e.g., **valproate** (Convulex): "The patient was treated with Convulex 300 mg/mL for the successful seizure control" (PMID: 34087865). (NCIT: Anticonvulsant Agent; Valproic Acid.)
- **Surgical repair of cleft palate** (NCIT: Cleft Palate Repair / Palatoplasty).
- **Treatment of associated anomalies**, e.g., levothyroxine for thyroid dysfunction where present (NCIT: Levothyroxine).
- **Developmental / rehabilitative therapy** — physical, occupational, and speech therapy (NCIT: Physical Therapy; Occupational Therapy; Speech Therapy).
- **Epilepsy surgery** may be considered for selected drug-resistant focal cases (NCIT: Epilepsy Surgery).

**Mechanistic/experimental target.** Because PVNH7 deregulates mTORC1/AKT, **mTOR inhibitors (rapamycin/sirolimus)** are a **theoretical** disease-mechanism target. This rationale is supported by rescue of mTORopathy phenotypes by rapamycin in animal models — "prenatal treatment with mTORC1 inhibitor rapamycin rescued the phenotype" in a Depdc5 mTORopathy model (PMID: 26873552) — and rapamycin reversed mTOR-dependent morphological/localization defects from GATOR1-subunit knockdown in neurons (PMID: 29481864). **No clinical trials of mTOR inhibition exist for PVNH7**, and the structural malformation is established prenatally, limiting postnatal disease modification.

**Pharmacogenomics / advanced therapeutics.** No PVNH7-specific pharmacogenomic guidance. No gene, cell, RNA-based, targeted, or immunotherapy is available or in trial for this indication.

---

## 13. Prevention

- **Primary prevention:** Not possible postnatally (malformation is congenital). For families with a known variant, options are preconception counseling, **preimplantation genetic testing (PGT)**, and **prenatal diagnosis**.
- **Secondary prevention:** Early MRI and genetic diagnosis enable early seizure management and developmental intervention.
- **Tertiary prevention:** Optimizing antiseizure therapy to prevent status epilepticus and developmental regression; multidisciplinary care to manage complications.
- **Genetic counseling:** Essential. Counseling must address the predominantly **de novo** origin, the documented **parental mosaicism** (which affects recurrence risk for apparently de novo cases; PMID: 30393983), and the **variable expressivity** that complicates prognostic prediction within families (PMID: 32117442).
- **Immunization / public health / environmental interventions:** Not applicable.

---

## 14. Other Species / Natural Disease

No naturally occurring animal disease equivalent to PVNH7 is cataloged (e.g., in OMIA). The gene is evolutionarily conserved: **Nedd4l/Nedd4-2 orthologs** exist in mouse (NCBI Gene: *Nedd4l*; *Mus musculus*, NCBI Taxon txid10090), rat (*Rattus norvegicus*, txid10116), and other vertebrates. Comparative mechanistic conservation is strong — mouse studies of Nedd4-2 (AMPA/GluA1 regulation and seizure susceptibility; ENaC regulation) directly inform the human mechanism. No zoonotic potential or cross-species transmission (not applicable — genetic developmental disorder).

---

## 15. Model Organisms

- **Mouse models [model organism].** The most informative is the **Nedd4-2-deficient mouse** (e.g., *Nedd4-2^andi^*), which shows elevated neuronal activity and increased kainic-acid seizure susceptibility, normalized by genetically reducing GluA1 — modeling the epilepsy arm of NEDD4L dysfunction (PMID: 28212375). **Conditional Nedd4-1/Nedd4-2 knockout mice** demonstrate that these ligases are required for axonal growth/branching in CNS neurons (PMID: 25157163).
- **In utero electroporation (mouse) [model organism].** The landmark functional system for PVNH7: expression of PNH-related mutants or excess wild-type NEDD4L in the developing mouse cortex reproduced defective neurogenesis, neuronal positioning, and terminal translocation, and revealed the AKT–mTORC1 and Dab1 mechanisms (PMID: 27694961). This is the best recapitulation of the **migration defect** underlying the nodules.
- **In vitro / cellular models [in vitro].** Patient-derived **lymphoblastoid cell lines** (showed only subtle AKT–mTOR changes — a model limitation highlighting context-dependence; Kato 2017) and expression constructs demonstrating proteasome sensitivity of mutants (PMID: 27694961) and protein-level destabilization (PMID: 36934385). Neuroblastoma (N2a) and neural progenitor cell systems are used to study mTORC1-dependent morphology in related mTORopathies (PMID: 29481864).
- **Related mTORopathy models [model organism].** The **Depdc5 knockout rat** (PMID: 26873552) and **DEPDC5/NPRL3 knockdown** neuronal models (PMID: 29481864) are not NEDD4L models but validate the mTORC1-rescue-by-rapamycin logic relevant to PVNH7's pathway.

**Recapitulation and limitations.** In utero electroporation recapitulates the core neuronal migration/heterotopia phenotype and the signaling deregulation well. Limitations: no single published model reproduces the **full human syndrome** (bilateral PNH + polymicrogyria + cleft palate + toe syndactyly) simultaneously; lymphoblastoid cells underrepresent the signaling phenotype; and dosage-sensitivity effects are hard to model precisely.

**Resources:** MGI (*Nedd4l*), IMPC/KOMP for knockout alleles, and standard mouse repositories.

---

## Mechanistic Model / Interpretation

PVNH7 is best understood as a **ubiquitin-ligase/mTOR-pathway "corticogenesis" disorder with dosage sensitivity.** The unifying model: a destabilizing, proteasome-sensitive HECT-domain missense change in NEDD4-2 perturbs the ligase's normal control over the AKT–mTORC1 growth-signaling axis and over Dab1/Reelin migration signaling. Because both mutant protein and excess wild-type protein are deleterious, the system is exquisitely sensitive to the **level and activity** of NEDD4-2 during a narrow fetal window of neurogenesis and radial migration. The consequence is twofold: (1) a **structural** failure of neurons to reach the cortex, producing bilateral periventricular nodules and polymicrogyria; and (2) an **excitability** liability, because NEDD4-2 normally throttles the AMPA-receptor GluA1 subunit, and its dysfunction lowers seizure threshold. The syndromic non-CNS features (cleft palate, toe syndactyly) reflect NEDD4-2's broader developmental roles. This model explains the clinical stratification — bilateral "PVNH-Plus" portends the worst epilepsy — and identifies **mTOR inhibition** as the only rational, if currently unproven and likely prenatal-window-limited, disease-mechanism target.

---

## Evidence Base

| PMID | Title (abbrev.) | Role |
|---|---|---|
| [PMID: 27694961](https://pubmed.ncbi.nlm.nih.gov/27694961/) | *Mutations in the HECT domain of NEDD4L lead to AKT-mTOR pathway deregulation and cause PNH* | **Landmark**: defines gene, HECT clustering, proteasome sensitivity, AKT-mTORC1/Dab1 mechanism, migration defect |
| [PMID: 28515470](https://pubmed.ncbi.nlm.nih.gov/28515470/) | *Missense mutation in HECT domain of NEDD4L… PNH, polymicrogyria, cleft palate* | De novo heterozygous inheritance; core phenotype; FLNA differential |
| [PMID: 31028281](https://pubmed.ncbi.nlm.nih.gov/31028281/) | *Author Correction* | Clarifies p.Glu873Lys = p.Glu893Lys is recurrent, not novel |
| [PMID: 32117442](https://pubmed.ncbi.nlm.nih.gov/32117442/) | *Recurrent NEDD4L Variant in PNH, Polymicrogyria and Syndactyly* | Familial p.Arg208Gln; variable expressivity; bilateral PNH + polymicrogyria |
| [PMID: 30393983](https://pubmed.ncbi.nlm.nih.gov/30393983/) | *Familial NEDD4L variant… and a fetus with hypokinesia* | Parental mosaicism; severe fetal spectrum |
| [PMID: 36934385](https://pubmed.ncbi.nlm.nih.gov/36934385/) | *Genetic analysis of PVNH7… Case and literature summary* | Trio-WES diagnosis; 8 variants/15 cases; protein (not mRNA) destabilization |
| [PMID: 34087865](https://pubmed.ncbi.nlm.nih.gov/34087865/) | *Admixed phenotype of NEDD4L-associated PNH* | Symptomatic valproate seizure control |
| [PMID: 31922594](https://pubmed.ncbi.nlm.nih.gov/31922594/) | *PVNH7 caused by NEDD4L variant* | p.Leu706Pro de novo, likely pathogenic (ACMG) |
| [PMID: 28212375](https://pubmed.ncbi.nlm.nih.gov/28212375/) | *Nedd4-2 mediates neuronal activity and seizure susceptibility through AMPA receptors* | Links NEDD4L to seizures via GluA1 (mouse) |
| [PMID: 12698368](https://pubmed.ncbi.nlm.nih.gov/12698368/) | *Nedd4/Nedd4-like ubiquitylation in epithelial transport* | Domain architecture; ENaC substrate |
| [PMID: 18498246](https://pubmed.ncbi.nlm.nih.gov/18498246/) | *Regulation of Nedd4-2 self-ubiquitination via HECT PY motif* | Protein stability regulation |
| [PMID: 16716084](https://pubmed.ncbi.nlm.nih.gov/16716084/) | *14-3-3 / SGK1 phosphorylation regulation of Nedd4-2* | Regulatory control of the ligase |
| [PMID: 20675381](https://pubmed.ncbi.nlm.nih.gov/20675381/) | *Hrs controls ENaC sorting (Nedd4-2)* | Canonical trafficking substrate biology; Liddle syndrome |
| [PMID: 25157163](https://pubmed.ncbi.nlm.nih.gov/25157163/) | *Nedd4-1 downstream of PI3K/PTEN-mTORC1 to promote neurite growth* | Places NEDD4 in mTOR network; axon growth |
| [PMID: 30683929](https://pubmed.ncbi.nlm.nih.gov/30683929/) | *Genomic CNVs in PNH — extreme heterogeneity* | Array-CGH as first-line test in PNH |
| [PMID: 37119372](https://pubmed.ncbi.nlm.nih.gov/37119372/) | *Phenotypic spectrum of epilepsy with PNH* | Epilepsy prognosis stratification; onset 7.9 y; 39% drug resistance in bilateral PVNH-Plus |
| [PMID: 37422633](https://pubmed.ncbi.nlm.nih.gov/37422633/) | *PNH associated with FLNA* | FLNA differential diagnosis |
| [PMID: 30547349](https://pubmed.ncbi.nlm.nih.gov/30547349/) | *FLNA mutations and interstitial lung disease* | FLNA phenotype distinction |
| [PMID: 26873552](https://pubmed.ncbi.nlm.nih.gov/26873552/) | *Depdc5 knockout rat: mTORopathy model* | Rapamycin rescue rationale |
| [PMID: 29481864](https://pubmed.ncbi.nlm.nih.gov/29481864/) | *DEPDC5/NPRL3 modulate mTOR in neurons* | Rapamycin-reversible mTOR phenotype |

---

## Limitations and Knowledge Gaps

1. **Ultra-rarity.** With only ~15 reported cases and 8 variants, all frequency estimates are qualitative; prevalence, incidence, penetrance, and sex ratio are unquantified.
2. **Mechanism context-dependence.** Robust AKT–mTORC1 deregulation is seen in overexpression/in-utero electroporation systems but is only subtle in patient lymphoblastoid cells (Kato 2017) — the quantitative in vivo mechanism remains uncertain, and whether gain-of-function, loss-of-function, or dominant-negative best describes individual variants is unresolved.
3. **No full-syndrome animal model.** Existing models capture either the migration defect or the seizure phenotype, not the complete human syndrome including cleft palate and syndactyly.
4. **No therapeutic evidence.** mTOR inhibition is purely theoretical for PVNH7; the structural lesion is prenatal, so postnatal disease modification may be inherently limited.
5. **Weak genotype–phenotype correlation**, confounded by marked intra-familial variability (p.Arg208Gln pedigree).
6. **No natural-history, QoL, or long-term outcome data** specific to PVNH7.

---

## Proposed Follow-up Experiments / Actions

1. **Establish an international PVNH7 registry** (GeneMatcher-based) to aggregate cases, variants, imaging, and outcomes — the single highest-value action given rarity.
2. **Variant-specific functional dissection** using isogenic human iPSC-derived cortical organoids/neurons carrying each recurrent variant (p.Glu893Lys, p.Leu706Pro, p.Tyr679His, p.Gln900Arg, p.Arg208Gln) to quantify effects on NEDD4-2 stability, ubiquitin-ligase activity, AKT–mTORC1 output, and Dab1/Reelin signaling in a human, non-overexpression context.
3. **Humanized/knock-in mouse models** of recurrent HECT variants to test whether the full syndrome is recapitulated and to perform **prenatal rapamycin rescue** experiments.
4. **GluA1/AMPA-receptor characterization** in patient-derived neurons to determine whether seizure susceptibility maps to the same GluA1 mechanism shown in Nedd4-2-deficient mice, which could nominate AMPA-receptor modulators (e.g., perampanel) as a mechanism-matched antiseizure choice.
5. **Systematic parental mosaicism screening** (deep sequencing of multiple tissues) in apparently de novo cases to refine recurrence-risk counseling.
6. **Prospective natural-history and QoL study** capturing seizure trajectory, developmental outcomes, and drug-resistance predictors across nodule distribution patterns.


## Artifacts

- [OpenScientist final report](Periventricular_Nodular_Heterotopia_7-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Periventricular_Nodular_Heterotopia_7-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.5.1.

| Outcome | Count |
| --- | --- |
| References checked | 20 |
| Resolved | 20 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 18 |
| Quoted claims found in source | 16 |
| Quoted claims **not** found in source | 2 |
| References weighed for topical relevance | 20 |
| On topic | 8 |
| Off topic | 2 |

### Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked *abstract only* below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

- `PMID:31922594` *(abstract only)*: "a heterozygous c.2117T>C (p.Leu706Pro) variant… a de novo variant… predicted to be likely pathogenic according to the American College of Medical Genetics Guidelines"
  - closest text in source: "RESULTS: The proband was found to carry a heterozygous c.2117T>C (p.Leu706Pro) variant of the NEDD4L gene, which was a de novo variant validated by Sanger sequencing and predicted to be likely pathogenic according to the American College of Medical Genetics Guidelines"
- `PMID:28212375` *(abstract only)*: "Nedd4-2 mediates neuronal activity and seizure susceptibility through ubiquitination of GluA1 subunit of the… AMPA receptor"
  - closest text in source: "In this study, we provide evidence to show that Nedd4-2 mediates neuronal activity and seizure susceptibility through ubiquitination of GluA1 subunit of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, (AMPAR)"

### References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

- `PMID:18498246` (5 mentions) - Regulation of Nedd4-2 self-ubiquitination and stability by a PY motif located within its HECT-domain.
  - shared terms: nedd4-2
- `PMID:20675381` (4 mentions) - Hrs controls sorting of the epithelial Na+ channel between endosomal degradation and recycling pathways.
  - shared terms: nedd4-2

Weighed against this report's own most characteristic terms: `pvnh7`, `seizure`, `nedd4l`, `developmental`, `palate`, `cleft`, `malformation`, `bilateral`, `neuron`, `nedd4-2`, `polymicrogyria`, `disease`, `novo`, `variant`, `mtorc1`, `pnh`, `syndactyly`, `disorder`, `gene`, `cortical`.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 28 |
| Resolved | 27 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 1 |
| Terms whose name was checked | 9 |
| Terms named correctly | 4 |
| Terms named as a **different** term | 5 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `MONDO:0014966` (2 mentions) - the report calls it "MONDO"; MONDO calls it **periventricular nodular heterotopia 7**
- `HP:0001252` (1 mention) - the report calls it "Clinical sign"; HP calls it **Hypotonia**
- `HP:0000308` (1 mention) - the report calls it "Physical malformation"; HP calls it **Microretrognathia**
- `HP:0000486` (1 mention) - the report calls it "Clinical sign"; HP calls it **Strabismus**
- `HP:0000047` (1 mention) - the report calls it "Physical malformation"; HP calls it **Hypospadias**